Neurocrine Biosciences (NBIX) Announces Conditional FDA Acceptance of Proposed Valbenazine Brand Name
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name "INGREZZA™" for the Company's once-daily vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine. The Company has recently announced the submission of a New Drug Application (NDA) with the FDA for valbenazine in tardive dyskinesia and is also exploring its utility in Tourette syndrome.
The name INGREZZA (pronounced in-GREH-zah) was developed using the FDA's Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names consistent with the goal of preventing medication errors. Additionally, the proprietary name development program included prescribers, pharmacists and linguists to create a unique, memorable name that helps to connote the clinical value of INGREZZA.
The NDA for INGREZZA includes the results from the Kinect 2 and Kinect 3 clinical trials which evaluated over 330 tardive dyskinesia patients. Data from these studies along with the results from another 18 clinical trials, extensive preclinical testing and drug manufacturing data were included in the NDA filing. The Company expects to receive notification of the acceptance of the NDA filing, as well as the timeframe for NDA review from the FDA in October 2016.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Clayton Williams Energy (CWEI) Enters Agreement to Sell Giddings Area Assets in $400M Deal; Names New COO
- Noah Holdings (NOAH) Announces RMB348M Investment From Sequoia Capital China
- Iron Mountain (IRM) Enters Agreement to Sell Iron Mountain Australian Business; Sees non-Cash Impairment in Q3
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!